Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Rabinowitz

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
European Journal of Applied Physiology|February 18, 2011
The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled studyShawn Portal, Zvi Zadik, Jonathan Rabinowitz, et al.
Biological Psychiatry|September 11, 2007
Subtle cognitive dysfunction in nonaffected siblings of individuals affected by nonpsychotic disordersMark Weiser, Abraham Reichenberg, Efrat Kravitz, et al.
Biological Psychiatry|September 18, 2003
Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophreniaMark Weiser, Abraham Reichenberg, Jonathan Rabinowitz, et al.
Journal of Clinical Psychopharmacology|December 31, 2010
Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectableJonathan Rabinowitz, Oleksandr Napryeyenko, Benjaminas Burba, et al.
The American Journal of Psychiatry|July 29, 2017
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in SchizophreniaMichael Davidson, Jay Saoud, Corinne Staner, et al.
Schizophrenia Research|November 29, 2020
Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP)Jonathan Rabinowitz, Mark Opler, Alon A Rabinowitz, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 2, 2007
Social and cognitive functioning, urbanicity and risk for schizophreniaMark Weiser, Jim van Os, Abraham Reichenberg, et al.
Schizophrenia Research|April 22, 2006
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based studyAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
Archives of General Psychiatry|December 7, 2005
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophreniaAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
JMIR Research Protocols|May 18, 2026
Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational StudyDan Cătălin Oprea, Ilinca Untu, Diana-Sabina Vieru, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
European Journal of Applied Physiology|February 18, 2011
The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled studyShawn Portal, Zvi Zadik, Jonathan Rabinowitz, et al.
Biological Psychiatry|September 11, 2007
Subtle cognitive dysfunction in nonaffected siblings of individuals affected by nonpsychotic disordersMark Weiser, Abraham Reichenberg, Efrat Kravitz, et al.
Biological Psychiatry|September 18, 2003
Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophreniaMark Weiser, Abraham Reichenberg, Jonathan Rabinowitz, et al.
Journal of Clinical Psychopharmacology|December 31, 2010
Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectableJonathan Rabinowitz, Oleksandr Napryeyenko, Benjaminas Burba, et al.
The American Journal of Psychiatry|July 29, 2017
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in SchizophreniaMichael Davidson, Jay Saoud, Corinne Staner, et al.
Schizophrenia Research|November 29, 2020
Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP)Jonathan Rabinowitz, Mark Opler, Alon A Rabinowitz, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 2, 2007
Social and cognitive functioning, urbanicity and risk for schizophreniaMark Weiser, Jim van Os, Abraham Reichenberg, et al.
Schizophrenia Research|April 22, 2006
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based studyAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
Archives of General Psychiatry|December 7, 2005
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophreniaAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
JMIR Research Protocols|May 18, 2026
Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational StudyDan Cătălin Oprea, Ilinca Untu, Diana-Sabina Vieru, et al.
Pageof 11